Nventa hires Vice President of Corporate Development



    - New Vice President Adds Significant Corporate and Business Development
    Experience -

    SAN DIEGO, CA, June 5 /CNW/ - Nventa Biopharmaceuticals Corporation
(TSX:NVN) announced today that Richard B. Lai Fatt, Ph.D., has joined the
Company as its Vice President of Corporate Development.
    "Richard is a results-oriented Business/Corporate Development
professional with substantial experience partnering novel drugs and drug
discovery programs," commented Gregory M. McKee, President and Chief Executive
Officer at Nventa. "His experience in all facets of Corporate and Business
Development, as well as hands-on expertise in strategic marketing and
planning, financial modeling, portfolio management and product
commercialization, will be invaluable as we advance our lead program, HspE7,
and identify synergistic opportunities to collaborate with other biotechnology
and pharmaceutical companies."
    Prior to joining Nventa, Dr. Lai Fatt was the Vice President of Corporate
Development at Kalypsys, Inc. Before Kalypsys, Dr. Lai Fatt served as Vice
President, Business Development and Strategic Marketing at Isis
Pharmaceuticals, where he secured several licensing and collaboration deals,
including partnerships with Merck and Amgen. Earlier in his career, Dr. Lai
Fatt held various positions at DuPont Merck Pharmaceuticals, Schering-Plough
International, Schering Canada and Lederle Pharmaceuticals.
    Dr. Lai Fatt received his B.Sc. at the University of Miami, Florida, and
his Ph.D. in biology at McMaster University in Hamilton, Ontario, Canada.

    About Nventa Biopharmaceuticals Corporation:
    --------------------------------------------
    Nventa is developing innovative therapeutics for the treatment of viral
infections and cancer, with a focus on diseases caused by the human
papillomavirus (HPV). The Company is publicly traded on the Toronto Stock
Exchange under the symbol NVN. For more information about Nventa
Biopharmaceuticals Corporation, please visit the Company's website located at
www.nventacorp.com.

    %SEDAR: 00023483E




For further information:

For further information: Donna Slade, Director, Investor Relations, 9381
Judicial Drive, Suite 180, San Diego, CA, USA, 92121, Dir: (858) 202-4945,
dslade@nventacorp.com

Organization Profile

NVENTA BIOPHARMACEUTICALS CORPORATION

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890